Reshaping what’s next in support of early lung cancer detection

Approximately 75% of lung cancer cases are diagnosed in an advanced stage.1 And with around 70% of cancerous lung nodules found in the outer third of the lung,2 diagnosing these cases early may prove challenging.

Through our years of collaboration with providers, it’s become increasingly clear that a pathway to support early lung cancer detection is imperative. By ushering in the Ion endoluminal system, a robotic-assisted bronchoscopy platform, we strive to support your teams in this endeavor.

Connect now

Innovation with intention

In the delicate and difficult-to-navigate environment of the lung, precision3 and stability3 are essential for confidence4 in navigation and biopsy. Explore Ion’s thoughtful design, driven by Intuitive’s collaboration with care providers.

Explore why physicians are choosing Ion. Get our brochure.

Discover more about Intuitive’s solutions

Receive access to a host of materials that include insights and experiences from your peers. We look forward to connecting and collaborating with you on what’s next for your organization.

 

By submitting my information, I am agreeing to receive information regarding Intuitive products and services and related topics. More information may be found in our privacy policy.

Form submission thank you

Thank you for registering.

We’ll be in touch.

  1. 75% patients found at stage 3 or 4 (advanced stage) – Walters S, et al. 2013. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax. 68, 551-564.
    In addition, approximately 79% of cancer cases are diagnosed at the regional or distant stage according to the SEER 18 2010-2016, All Races, Both Sexes by SEER Summary Stage 2000 data: https://seer.cancer.gov/statfacts/html/lungb.html.
  2. Horeweg, et al. Characteristics of Lung Cancer Detected by Computer Tomography Screening in the Randomized NELSON Trial. ATS Journal Vol 187, 848-854, Apr 15, 2013.
  3. Precision is the ability to place a biopsy tool in the desired location consistently. Flexibility is the ability to articulate 180° in all directions. Reach is defined by airway generation access. Stability (or unprecedented stability) reflect enablement by fiber optic sensing technology which maintains active robotic control of catheter position and corrects unwanted tip deflection. Results based on internal testing.
  4. Confidence is in reference to the stability, precision, and reach capable with Ion enabling the placement of biopsy tools in the desired location.
  5. Results based on internal testing. Data on file.

Important safety information

Risks associated with bronchoscopy through an endotracheal tube and under general anesthesia are infrequent and typically minor, and may include but are not limited to: sore throat, hoarseness, respiratory complications including dyspnea or hypoxemia, airway injury, bronchospasm, laryngospasm, fever, hemoptysis, chest or lung infection including pneumonia, lung abscess or an adverse reaction to anesthesia. Although rare, the following complications may also occur: bleeding, pneumothorax (collapsed lung), cardiac related complications, respiratory failure, air embolism, or death. As with other medical procedures, there may be additional risks associated with the use of general anesthesia and/or endotracheal intubation which are not listed above; you should consult a health care professional regarding these and other potential risks.

Procedures using the Ion Endoluminal System may be associated with longer procedure and/or longer anesthesia time.

Individuals’ outcomes may depend on a number of factors—including but not limited to—patient characteristics, disease characteristics, and/or physician experience.

Ion endoluminal system

The Ion endoluminal system (Model IF1000) assists the user in navigating a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures. The Ion endoluminal system enables fiducial marker placement. It does not make a diagnosis and is not for pediatric use.

Information provided by the Ion endoluminal system or its components should be considered guidance only and not replace clinical decisions made by a trained physician.

The Flexision Biopsy Needle is used with the Ion Endoluminal System to biopsy tissue from a target area in the lung.

The PlanPoint Software uses patient CT scans to create a 3D plan of the lung and navigation pathways for use with the Ion Endoluminal System.